Chau Khuong, MPH

Chau Q. Khuong is a biotech entrepreneur and venture capital investor. From 2003 until 2021, he worked at OrbiMed Advisors, a global healthcare-dedicated investment firm with over $15 billion in assets under management. At the time of his retirement from OrbiMed, Chau was Partner and member of the investment committee for the OrbiMed venture capital funds.  Over the past two decades, he was an active lead investor in innovative drug development and medical device enterprises across all stages and therapeutic areas including oncology, infectious diseases, ophthalmology, gene therapy and gene editing. Chau has served in a Board of Directors capacity of numerous public and private companies, including Arius Research (acquired by Roche), Durata (acquired by Actavis), Glaukos Medical (NYSE: GKOS), Intellia Pharmaceuticals (NASDAQ: NTLA), Intercept Pharmaceuticals (NASDAQ: ICPT), Inspire Medical Systems (NYSE: INSP). He holds a BS in molecular, cellular and developmental biology with a concentration in biotechnology and an MPH with a concentration in infectious diseases, both from Yale University.